Eli Lilly 2012 Annual Report Download - page 27

Download and view the complete annual report

Please find page 27 of the 2012 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 164

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164

15
that term is defined for purposes of this disclosure requirement. There is no understanding between any
executive officer and any other person pursuant to which the executive officer was selected.
Name Age Offices and Business Experience
John C. Lechleiter, Ph.D. 59 Chairman (since January 2009), President (since October 2005), Chief Executive Officer (since April
2008), and a Director (since October 2005)
Robert A. Armitage 64 Senior Vice President and General Counsel (since January 2003) (retired December 2012)
Melissa S. Barnes 44 Senior Vice President, Enterprise Risk Management and Chief Ethics and Compliance Officer (since
January 2013)
Enrique A. Conterno 46 Senior Vice President and President, Lilly Diabetes (since November 2009)
Maria A. Crowe 53 President, Manufacturing Operations (since January 2012)
Stephen F. Fry 47 Senior Vice President, Human Resources and Diversity (since February 2011)
Michael J. Harrington 50 Senior Vice President and General Counsel (since January 2013)
Jan M. Lundberg, Ph.D. 59 Executive Vice President, Science and Technology, and President, Lilly Research Laboratories (since
January 2010). From 2002 until he joined Lilly in January 2010, Dr. Lundberg was executive vice
president and head of discovery research at AstraZeneca.
Susan Mahony, Ph.D. 48 Senior Vice President and President, Lilly Oncology (since February 2011)
Anne Nobles 56 Senior Vice President, Enterprise Risk Management (since April 2009) and Chief Ethics and
Compliance Officer (since June 2007) (retired December 2012)
Barton R. Peterson 54 Senior Vice President, Corporate Affairs and Communications (since June 2009). Mr. Peterson served
as mayor of Indianapolis, Indiana from 2000 to 2007. From 2008 to 2009, he was managing director at
Strategic Capital Partners, LLC, and distinguished visiting professor of public policy at Ball State
University.
Derica W. Rice 48 Executive Vice President, Global Services (since January 2010) and Chief Financial Officer (since May
2006)
David A. Ricks 45 Senior Vice President and President, Lilly Bio-Medicines (since January 2012)
Jeffrey N. Simmons 45 Senior Vice President and President, Elanco Animal Health (since January 2008)
Jacques Tapiero 54 Senior Vice President and President, Emerging Markets (since January 2010)
Fionnuala M. Walsh 53 Senior Vice President, Global Quality (since July 2007)
Employees
At the end of 2012, we employed approximately 38,350 people, including approximately 21,200 employees
outside the United States. A substantial number of our employees have long records of continuous service.
Financial Information Relating to Business Segments and Classes of Products
You can find financial information relating to our business segments and classes of products in Item 8,
"Financial Statements and Supplementary Data—Segment Information." That information is incorporated
here by reference.
The relative contribution of any particular product to our consolidated revenue changes from year to year. This
is due to several factors, including the introduction of new products by us and by other manufacturers and the
introduction of generic pharmaceuticals upon patent expirations. Our major product revenues are generally
not seasonal.
Financial Information Relating to Foreign and Domestic Operations
You can find financial information relating to foreign and domestic operations in Item 8, “Financial Statements
and Supplementary Data—Segment Information.” That information is incorporated here by reference. To date,
our overall operations abroad have not been significantly deterred by local restrictions on the transfer of
funds from branches and subsidiaries located abroad, including the availability of U.S. dollar exchange. We
cannot predict what effect these restrictions or the other risks inherent in foreign operations, including
possible nationalization, might have on our future operations or what other restrictions may be imposed in the